Mike Kratky
Stock Analyst at Leerink Partners
(3.93)
# 912
Out of 4,667 analysts
26
Total ratings
77.78%
Success rate
61.92%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $75.24 | +15.63% | 2 | Oct 25, 2024 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $167 → $197 | $184.77 | +6.62% | 2 | Sep 10, 2024 | |
| TXG 10x Genomics | Initiates: Outperform | $35 | $13.32 | +162.76% | 1 | Sep 3, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $239.20 | +9.95% | 1 | Sep 3, 2024 | |
| NARI Inari Medical | Initiates: Market Perform | $47 | $49.00 | -4.08% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $30.15 | +49.25% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $9.19 | +139.39% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $266.58 | -30.98% | 1 | Oct 16, 2023 | |
| VCEL Vericel | Initiates: Outperform | $42 | $57.26 | -26.65% | 1 | Oct 16, 2023 | |
| ISRG Intuitive Surgical | Initiates: Outperform | $342 | $541.82 | -36.88% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $69.54 | +7.85% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $92.70 | -60.09% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $12.90 | -30.23% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $5.81 | +760.59% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $12.73 | +253.50% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $317.09 | -0.66% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $44.05 | -29.63% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $26.17 | -46.50% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $19.79 | +102.12% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $48 | $1.07 | +4,385.98% | 1 | Aug 11, 2022 |
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $75.24
Upside: +15.63%
Inspire Medical Systems
Sep 10, 2024
Maintains: Market Perform
Price Target: $167 → $197
Current: $184.77
Upside: +6.62%
10x Genomics
Sep 3, 2024
Initiates: Outperform
Price Target: $35
Current: $13.32
Upside: +162.76%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $239.20
Upside: +9.95%
Inari Medical
Sep 3, 2024
Initiates: Market Perform
Price Target: $47
Current: $49.00
Upside: -4.08%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $30.15
Upside: +49.25%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $9.19
Upside: +139.39%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $266.58
Upside: -30.98%
Vericel
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $57.26
Upside: -26.65%
Intuitive Surgical
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $541.82
Upside: -36.88%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $69.54
Upside: +7.85%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $92.70
Upside: -60.09%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $12.90
Upside: -30.23%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $5.81
Upside: +760.59%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $12.73
Upside: +253.50%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $317.09
Upside: -0.66%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $44.05
Upside: -29.63%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $26.17
Upside: -46.50%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $19.79
Upside: +102.12%
Aug 11, 2022
Maintains: Outperform
Price Target: $49 → $48
Current: $1.07
Upside: +4,385.98%